The high frequency of CDK4/6 pathway activation in cancer more broadly has led to the development of CDK4/6 inhibitors, such as palbociclib, ribociclib and abemaciclib [9], and the therapeutic effects of palbociclib have been studied in the context of BRAF inhibitor resistance in melanoma. The gene discussed is CDK4; the disease is cancer.